{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:58Z","timestamp":1793970898533,"version":"4.8.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome are nonmalignant but life-threatening systemic inflammatory disorders. However, many patients are refractory to treatment, resulting in significant morbidity and mortality. Additionally, established treatment options are unavailable. Therefore, we present 2 cases of adults with the iMCD-TAFRO syndrome refractory to initial treatment but responded to Janus kinase (JAK) inhibitors with ruxolitinib. The report reveals that these rare adult cases of the refractory and treatment-resistant iMCD-TAFRO syndrome can be treated using JAK inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Case 1 is a 36-year-old previously healthy male patient who presented with fever and general fatigue for 2 weeks. Case 2 is a 42-year-old previously healthy female patient who presented with fever and general fatigue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The diagnosis met the 2015 criteria for TAFRO syndrome, as determined by All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Treatment with tocilizumab and several immunosuppressants were ineffective. So, we performed ruxolitinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Each patient received ruxolitinib, the general condition improved, and CRP levels decreased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>These cases showed that ruxolitinib was effective for treatment-resistant\/ refractory TAFRO syndrome. Further prospective studies are needed on using ruxolitinib with a small number of cases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032200","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:08:36Z","timestamp":1670515716000},"page":"e32200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-8581","authenticated-orcid":false,"given":"Takuya","family":"Kakutani","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Shonan Kamakura General Hospital, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nunokawa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Tama Nambu Chiiki Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Chinen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Tama Nambu Chiiki Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Shonan Kamakura General Hospital, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.semdp.2016.05.006","article-title":"Multicentric Castleman disease: where are we now?","volume":"33","author":"Wang","year":"2016","journal-title":"Semin Diagn Pathol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JBM.S127822","article-title":"TAFRO syndrome: current perspectives.","volume":"9","author":"Sakashita","year":"2018","journal-title":"J Blood Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease.","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomized, double-blind, placebo-controlled trial.","volume":"15","author":"Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.xkme.2020.10.011","article-title":"TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies.","volume":"3","author":"Shimada","year":"2021","journal-title":"Kidney Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","article-title":"TAFRO syndrome.","volume":"32","author":"Igawa","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/24725625.2020.1789304","article-title":"Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab.","volume":"5","author":"Wakiya","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2169\/internalmedicine.8522-16","article-title":"Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide.","volume":"56","author":"Kikuchi","year":"2017","journal-title":"Intern Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1159\/000518079","article-title":"TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy.","volume":"14","author":"Williams","year":"2021","journal-title":"Case Rep Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease.","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"},{"key":"R13-20250504","first-page":"e23291e23291","article-title":"An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease. Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).","volume":"99","author":"Koga","year":"2020","journal-title":"Medicine"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","article-title":"Type \u2160 IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.","volume":"5","author":"Langan Pai","year":"2020","journal-title":"JCI Insight"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type \u2160 interferon responses.","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type \u2160 interferons in autoimmune disease.","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/jidsymp.2013.29","article-title":"Janus Kinases: Ann ideal target for the treatment of autoimmune diseases.","volume":"16","author":"Massimo","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK Inhibition for the treatment of myelofibrosis: limitations and future perspectives.","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e29261","DOI":"10.1002\/pbc.29261","article-title":"Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series.","volume":"68","author":"Lust","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"719","DOI":"10.7326\/L20-1051","article-title":"JAK 1\/2 inhibition in severe TAFRO syndrome: a case report.","volume":"174","author":"Killian","year":"2021","journal-title":"Ann Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:32:40Z","timestamp":1746333160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":20,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032200","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}